I-MAB Regains Global Rights To Lemzoparlimab; Received Notice On Sept 21 From AbbVie Global Enterprises Terminating License, Collaboration Agreement Between Parties Dated Sept 3, 2020
Portfolio Pulse from Benzinga Newsdesk
I-MAB has regained global rights to Lemzoparlimab after receiving a termination notice from AbbVie Global Enterprises on their license and collaboration agreement dated Sept 3, 2020.
September 22, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's termination of the license and collaboration agreement with I-MAB could indicate a lack of confidence in the potential success of Lemzoparlimab.
AbbVie's decision to terminate the agreement could be seen as a lack of confidence in the drug's potential success, which could negatively impact investor sentiment towards AbbVie.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 75
POSITIVE IMPACT
I-MAB regains global rights to Lemzoparlimab, which could potentially impact their revenue positively if the drug proves successful.
I-MAB regaining global rights to Lemzoparlimab means they have full control over the drug's development and potential profits. This could be positive for the company if the drug proves successful and gains market approval.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100